RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Relief Therapeutics announced that its collaboration partner, NRx Pharmaceuticals, has filed for Breakthrough Therapy Designation from the FDA for aviptadil aimed at treating COVID-19 patients experiencing respiratory failure. The BTD request is supported by clinical data showing a 2.8-fold increase in survival odds at 28 days and a 4-fold increase at 60 days for patients treated with aviptadil compared to a placebo. This data may significantly impact Relief's market position and investor sentiment regarding its ongoing clinical programs.

Relief Therapeutics announced that the Swiss Patent Office will conclude its patent application for Vasoactive Intestinal Peptide (VIP) by January 24, 2022. This patent, focusing on the treatment of drug-induced pneumonitis via the inhaled formulation of RLF-100 (aviptadil), underlines the company’s strengthening intellectual property portfolio. Chairman Raghuram Selvaraju emphasized the significance of this patent amidst ongoing clinical studies, which indicate promising results for patients suffering from immune checkpoint inhibitor-related pneumonitis. The patent is expected to be issued a month after the examination procedure concludes.

Relief Therapeutics Holding SA has filed a Registration Statement on Form 20-F with the U.S. SEC, aiming to upgrade its Level 1 American Depositary Receipt (ADR) program to Level 2. This move supports Relief's ambition to list on the NASDAQ during the first half of 2022, pending SEC approval and application. Currently, the company's ordinary shares are traded on the SIX Swiss Exchange under the symbol RLF and on OTCQB under RLFTF. The ADRs represent 150 of Relief's ordinary shares and currently trade as RLFTY.

Relief Therapeutics Holding SA announced that its collaboration partner, NRx Pharmaceuticals, reported a favorable safety update on aviptadil, currently being tested in the ACTIV-3b Critical Care Phase 3 study by the NIH. The Independent Data Safety Monitoring Board reviewed 348 patients and found no new safety concerns, allowing the study to continue enrollment aiming for a total of 640 patients. This update supports Relief's lead candidate, RLF-100 (aviptadil), which is in late-stage testing for respiratory deficiencies due to COVID-19.

Relief Therapeutics reported that its partner, NRx Pharmaceuticals, has established a regulatory pathway with Hungarian Health Officials for the emergency use of aviptadil. This program is expected to commence by the end of 2021. Relief is focused on clinical-stage programs, notably advancing RLF-100 (aviptadil) for COVID-19 related respiratory issues. The company also diversifies its pipeline through agreements like the one with Acer Therapeutics for ACER-001 aimed at treating Urea Cycle Disorders.

Relief Therapeutics announces key executive changes aimed at strengthening its leadership team. Nermeen Varawalla has been appointed as Chief Medical Officer, replacing Gilles Della Corte. Varawalla brings over 30 years of experience in the pharmaceutical sector, focusing on clinical trials and regulatory expertise. Jeremy Meinen is promoted to Chief Accounting Officer, while Marco Marotta takes on the role of Chief Business Officer, overseeing business development. These strategic appointments align with Relief's goal to expand its clinical pipeline.

Relief Therapeutics (OTCQB: RLFTF, RLFTY) announced a significant breakthrough in treating Critical COVID-19 with aviptadil, indicating better outcomes compared to remdesivir. An analysis led by Prof. David Schoenfeld showed a 2.5-fold increase in the odds of patients recovering from respiratory failure and a four-fold higher chance of survival at 60 days. This highlights the potential of aviptadil as an effective treatment for severe cases of COVID-19, offering hope in serious disease management.

Relief Therapeutics has entered a collaboration with InveniAI to identify new drug candidates for rare diseases using AI technologies. InveniAI's proprietary AlphaMeld platform will analyze data from regulatory-approved drugs to find potential therapies. Relief will compensate InveniAI with an initial fee, milestone payments, and royalties. The partnership aims to leverage AI for efficient drug development while enhancing Relief's existing capabilities through its subsidiary APR Applied Pharma Research. This collaboration could lead to innovative product concepts for patients with severe conditions.

Relief Therapeutics announced that its collaboration partner, NRx Pharmaceuticals, received notice from the FDA denying Breakthrough Therapy Designation for aviptadil. While this designation could have expedited the review process, it is not a requirement for drug approval. The FDA had previously granted priority and rolling review under Fast Track Designation. NRx emphasized that potential approval remains viable, but acknowledges the need for improved scientific alignment. Relief continues to advance its clinical programs, including RLF-100 for COVID-19 respiratory issues.